To develop a standardized, validated tool for evaluating fingernail psoriasis severity that addresses limitations of existing assessment tools.
Approach:
Key Findings:
ViSENPsO provides a user-friendly alternative to existing tools, improving consistency and reliability in nail psoriasis assessment.
The scale was developed through rigorous qualitative and quantitative methodologies involving both clinicians and patients.
Further psychometric validation is needed in larger, diverse populations to confirm its applicability.
Interpretation:
The ViSENPsO scale addresses the shortcomings of the Nail Psoriasis Severity Index by offering a more precise and reliable method for assessing nail psoriasis severity.
Limitations:
Further validation in larger and more diverse populations is required.
The study primarily involved dermatologists and patients from specific regions, which may limit generalizability.
Conclusion:
The ViSENPsO scale represents a significant advancement in the assessment of nail psoriasis severity, with potential for improved outcomes in clinical trials.
Published evidence linked liraglutide and semaglutide to improvements in psoriasis severity, inflammatory markers, and metabolic outcomes, while evidence in psoriatic arthritis remained sparse.
The expanded indication is supported by pharmacokinetic, safety, tolerability, exploratory efficacy, and long-term safety data from studies in children aged 2 to 5 years.